분자진단 시장 : 제공 서비스별, 기술별, 검체 유형별, 검사 유형별, 용도별, 최종 사용자별 - 세계 시장 예측(2026-2032년)

The Molecular Diagnostics Market is projected to grow by USD 34.27 billion at a CAGR of 9.70% by 2032.

Molecular diagnostics is moving from a specialized laboratory discipline to a core pillar of precision medicine, public health surveillance, and biopharma development. Demand is supported by the clinical value of PCR, RT-PCR, digital PCR, next-generation sequencing, liquid biopsy, companion diagnostics, and point-of-care molecular testing across infectious disease, oncology, inherited disease, reproductive health, and antimicrobial resistance management.

Evidence-based demand drivers remain strong. IARC reported nearly 20 million new cancer cases globally in 2022, while the WHO has highlighted tuberculosis, HIV, viral hepatitis, and antimicrobial resistance as persistent priorities requiring accurate and timely testing. For healthcare systems, molecular diagnostics improves early detection, therapy selection, outbreak response, and treatment monitoring, making it a strategic investment area rather than a discretionary laboratory expense.

Transformative Shifts in the Molecular Diagnostics Landscape

The molecular diagnostics landscape is being reshaped by decentralization, automation, syndromic testing, and the shift from single-analyte assays to multiplex and sequencing-based workflows. COVID-19 accelerated molecular testing capacity worldwide, but the longer-term shift is broader: hospitals, reference laboratories, and public health agencies are now applying molecular tools to respiratory infections, sepsis, oncology, transplant monitoring, pharmacogenomics, and rare disease diagnosis.

Regulation is also transforming market behavior. The European Union In Vitro Diagnostic Regulation has raised requirements for clinical evidence and post-market surveillance, while the United States continues to scrutinize laboratory-developed tests and companion diagnostic pathways. These changes favor manufacturers and laboratories with validated assays, scalable quality systems, strong clinical evidence, and integrated informatics.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a cumulative force across molecular diagnostics, improving assay design, variant interpretation, quality control, laboratory workflow optimization, and clinical decision support. AI is especially relevant in next-generation sequencing, where algorithms help prioritize variants, interpret complex genomic signatures, and connect molecular findings with evidence-based therapy options.

The impact is not limited to analytics. AI-enabled automation can reduce manual review, support capacity planning, improve sample routing, and detect anomalies in high-throughput laboratories. However, adoption must be governed by transparent validation, cybersecurity, data provenance, bias monitoring, and alignment with evolving oversight frameworks, including FDA activity on AI-enabled medical devices and the EU AI Act.

Key Regional Insights

Asia-Pacific is one of the fastest-evolving molecular diagnostics regions due to expanding hospital networks, rising cancer burden, infectious disease surveillance needs, and investment in genomics across China, India, Japan, South Korea, Australia, and ASEAN markets. National programs supporting tuberculosis testing, viral disease surveillance, cancer screening, and rare disease diagnosis are strengthening demand for PCR, NGS, and decentralized molecular platforms. North America remains the leading innovation and reimbursement reference point, supported by advanced laboratory infrastructure, FDA-cleared and laboratory-developed testing ecosystems, oncology companion diagnostics, public health sequencing, and strong biopharma demand.

Europe is shaped by IVDR implementation, national health technology assessment discipline, established screening programs, and growing use of molecular oncology and antimicrobial resistance testing. Latin America is gaining momentum through private laboratory consolidation, expanding hospital access, and infectious disease testing needs in Brazil, Mexico, and other urban healthcare systems. The Middle East is investing in national genomics, tertiary hospitals, and precision medicine programs, particularly across GCC countries, while Africa's opportunity is closely tied to tuberculosis, HIV, malaria, emerging pathogen surveillance, outbreak preparedness, and scalable point-of-care molecular diagnostics suited to decentralized care settings.

Key Group Insights

ASEAN demand is expanding as Indonesia, Thailand, Vietnam, Malaysia, Singapore, and the Philippines invest in hospital diagnostics, infectious disease preparedness, oncology capacity, and laboratory modernization. The GCC is advancing molecular diagnostics through precision medicine initiatives, tertiary care expansion, premarital and newborn screening programs, and national genome initiatives that support inherited disease, cancer testing, and population health planning.

The European Union is defined by IVDR compliance, cross-border evidence standards, reimbursement scrutiny, and the need for clinically validated assays that can meet post-market performance requirements. BRICS countries combine large patient populations with growing local manufacturing, genomics capacity, and public health priorities in tuberculosis, cancer, and infectious disease surveillance. G7 markets remain the benchmark for high-complexity molecular testing, companion diagnostics, laboratory automation, and advanced reimbursement models, while NATO economies also place strategic value on biosecurity, pathogen surveillance, and resilient diagnostic supply chains.

Key Country Insights

The United States leads in molecular diagnostics innovation through advanced reference laboratories, FDA-cleared assays, oncology NGS, liquid biopsy, newborn screening, and companion diagnostic adoption. Canada benefits from public health laboratory strength, genomics initiatives, and coordinated infectious disease surveillance, while Mexico and Brazil are expanding private diagnostic networks, hospital-based molecular testing, and infectious disease capabilities. The United Kingdom, Germany, France, Italy, and Spain are shaped by national health systems, cancer strategies, antimicrobial resistance priorities, and IVDR-driven evidence requirements, while Russia maintains demand across infectious disease testing, oncology diagnostics, and hospital-based molecular workflows.

China is scaling domestic IVD manufacturing, oncology testing, sequencing capacity, and public health molecular infrastructure, while India is expanding affordable PCR, tuberculosis testing, oncology diagnostics, and decentralized laboratory access under a healthcare system that continues to prioritize infectious disease control and cancer care. Japan and South Korea remain leaders in automation, oncology diagnostics, genomic medicine, and high-quality clinical laboratory standards. Australia benefits from mature reimbursement structures, public health surveillance, established genetic testing pathways, and strong adoption of advanced infectious disease and inherited disease testing.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically validated molecular diagnostics with clear utility in patient management, reimbursement, and workflow efficiency. Assay portfolios should balance high-volume infectious disease testing with higher-value oncology, pharmacogenomics, reproductive health, antimicrobial resistance, and transplant applications, while platforms should support automation, interoperability, sample-to-answer workflows, and scalable menu expansion.

Commercial strategy should align with regional regulation and evidence expectations. Organizations should invest in IVDR readiness, FDA engagement, companion diagnostic partnerships, AI governance, cybersecurity, data privacy, decentralized testing models, and supply chain resilience for reagents and consumables. Laboratories should reduce turnaround time through integrated workflows and build partnerships with hospitals, payers, public health agencies, and biopharma sponsors to demonstrate measurable clinical and operational outcomes.

Research Methodology

This executive summary is based on secondary research from recognized public health, regulatory, clinical, and industry sources, including the WHO, IARC, CDC, FDA, EMA, OECD, World Bank, national health agencies, peer-reviewed medical literature, clinical guideline bodies, and publicly available regulatory documentation. The analysis emphasizes verified demand drivers, disease burden indicators, regulatory developments, technology adoption patterns, and region-specific healthcare infrastructure signals.

Insights were synthesized using a triangulation approach that compares disease burden, installed laboratory capacity, regulatory requirements, reimbursement maturity, procurement behavior, technology readiness, and public health priorities. The methodology prioritizes evidence-backed interpretation over speculative forecasting and is designed to support strategic planning for molecular diagnostics manufacturers, laboratories, investors, and healthcare decision-makers.

Conclusion

Molecular diagnostics is entering a more evidence-driven and digitally enabled phase, where clinical value, regulatory compliance, automation, and data interpretation determine competitive advantage. The field is expanding beyond pandemic-era testing into durable applications across oncology, infectious disease, genetic testing, companion diagnostics, antimicrobial resistance management, and public health surveillance.

Organizations that combine validated assays, AI-supported interpretation, strong quality systems, interoperable platforms, and region-specific access strategies will be best positioned to capture growth opportunities without relying on speculative demand assumptions. As healthcare systems prioritize earlier diagnosis and targeted treatment, molecular diagnostics will remain essential to precision medicine, resilient public health infrastructure, and measurable patient outcomes.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Molecular Diagnostics Market, by Offering

• 7.1. Instruments
• 7.2. Reagents & Kits
• 7.3. Software & Services

8. Molecular Diagnostics Market, by Technology

• 8.1. Fluorescence In Situ Hybridization
• 8.2. Mass Spectrometry
• 8.3. Microarray Analysis
• 8.4. Next-Generation Sequencing
  • 8.4.1. Exome Sequencing
  • 8.4.2. RNA Sequencing
  • 8.4.3. Targeted Sequencing
  • 8.4.4. Whole Genome Sequencing
• 8.5. Polymerase Chain Reaction
  • 8.5.1. Digital PCR
  • 8.5.2. Multiplex PCR
  • 8.5.3. Real-Time PCR

9. Molecular Diagnostics Market, by Specimen Type

• 9.1. Blood
• 9.2. Cerebrospinal Fluid (CSF)
• 9.3. Nasal/Throat Swabs
• 9.4. Saliva
• 9.5. Stool
• 9.6. Tissue Biopsies
• 9.7. Urine

10. Molecular Diagnostics Market, by Test Type

• 10.1. Point Of Care
• 10.2. Laboratory Based

11. Molecular Diagnostics Market, by Application

• 11.1. Genetic Testing
  • 11.1.1. Carrier Testing
  • 11.1.2. Diagnostic Testing
  • 11.1.3. Predictive Testing
• 11.2. Infectious Disease
  • 11.2.1. Bacterial
  • 11.2.2. Parasitic
  • 11.2.3. Viral
• 11.3. Oncology
  • 11.3.1. Liquid Biopsy
  • 11.3.2. Minimal Residual Disease
  • 11.3.3. Tissue Biopsy
• 11.4. Prenatal Testing
  • 11.4.1. Invasive
  • 11.4.2. Non-Invasive

12. Molecular Diagnostics Market, by End User

• 12.1. Academic & Research Institutes
• 12.2. Diagnostic Laboratories
• 12.3. Hospitals & Clinics

13. Molecular Diagnostics Market, by Region

• 13.1. Asia-Pacific
• 13.2. North America
• 13.3. Latin America
• 13.4. Europe
• 13.5. Middle East
• 13.6. Africa

14. Molecular Diagnostics Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Molecular Diagnostics Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Concentration Analysis, 2025
  • 16.1.1. Concentration Ratio (CR)
  • 16.1.2. Herfindahl Hirschman Index (HHI)
• 16.2. Recent Developments & Impact Analysis, 2025
• 16.3. Product Portfolio Analysis, 2025
• 16.4. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. Abbott Laboratories Inc.
• 17.2. Adaptive Biotechnologies Corporation
• 17.3. ADT Biotech Co., Ltd.
• 17.4. Agena Bioscience, Inc.
• 17.5. AstraZeneca plc
• 17.6. Becton, Dickinson and Company
• 17.7. BGI Genomics Co., Ltd.
• 17.8. Bio-Rad Laboratories, Inc.
• 17.9. Bio-Techne Corporation
• 17.10. Biocartis Group NV
• 17.11. bioMerieux SA
• 17.12. Bioneer Corporation
• 17.13. Castle Biosciences, Inc.
• 17.14. Danaher Corporation
• 17.15. Diasorin S.p,A.
• 17.16. Exact Sciences Corporation
• 17.17. F. Hoffmann-La Roche AG
• 17.18. Genomadix Inc.
• 17.19. Grifols S.A.
• 17.20. Guardant Health, Inc.
• 17.21. Hologic, Inc.
• 17.22. Illumina, Inc.
• 17.23. Laboratory Corporation of America Holdings
• 17.24. Meridian Bioscience, Inc.
• 17.25. Myriad Genetics, Inc.
• 17.26. Oxford Gene Technology by Sysmex Corporation
• 17.27. QIAGEN N.V.
• 17.28. Siemens Healthineers AG
• 17.29. Source BioScience
• 17.30. Thermo Fisher Scientific Inc.